Page last updated: 2024-12-05

4-hydroxypropiophenone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Occurs in Manufacturing Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID6271
CHEMBL ID312311
CHEBI ID32352
SCHEMBL ID440470
MeSH IDM0188862

Synonyms (133)

Synonym
chebi:32352 ,
CHEMBL312311 ,
F1995-0235
hypostat
4-hydroxypropiophenone
1-(4-hydroxyphenyl)-1-propanone
possipione
paraoxypropiophenone
b 360
p-oxypropiophenone
70-70-2
1-(p-hydroxyphenyl)-1-propanone
p-hydroxypropiophenone
p-hydroxyphenyl-1-propanone
p-propionylphenol
frenantol
wln: qr dv2
frenormon
h-365
p-propiophenol
mepal
profenone
hypophenon
proxiphenon
ethyl p-hydroxyphenyl ketone
frenon
4-propionylphenol
4'-hydroxypropiophenone
h 365
1-propanone, 1-(4-hydroxyphenyl)-
b-360
propiophenone, 4'-hydroxy-
paroxypropione
ibiopopp
usaf ek-3302
paroxon
nsc2834
sterofenon
bio-fren
frenohypon
nsc-2834
paroxypropion
MLS000069406 ,
nsc33949
nsc-33949
1-(4-hydroxyphenyl)propan-1-one
para-hydroxypropiophenone
paroxypropione [inn:dcf]
einecs 200-743-2
parossipropione [dcit]
paroxypropionum [inn-latin]
brn 0907511
ai3-03719
nsc 2834
paroxipropiona [inn-spanish]
4'-hydroxypropiophenone, 98%
p-hydroxypropiophenone (jan)
paroxypropione (inn)
D01870
smr000059092
NCGC00018097-01
NCGC00022475-04
NCGC00022475-03
STK397478
AC-10985
1-(4-hydroxy-phenyl)-propan-1-one
bdbm50177402
4''-hydroxypropiophenone
H0299
ethyl 4-hydroxyphenyl ketone
NCGC00018097-04
AKOS000120374
NCGC00018097-05
NCGC00018097-06
NCGC00018097-03
NCGC00018097-02
AF-676/00077028
HMS3264A14
1-(4-hydroxyphenyl)-propan-1-one
BBL011845
nsc760386
pharmakon1600-01506169
nsc-760386
cas-70-70-2
tox21_110822
dtxcid103426
dtxsid8023426 ,
HMS2235G15
vanatone
paroxipropiona
x9952001tg ,
parossipropione
unii-x9952001tg
paroxypropionum
4-08-00-00441 (beilstein handbook reference)
FT-0618741
S5396
HMS3372E08
paroxypropione [who-dd]
paroxypropione [mi]
paroxypropione [inn]
paroxypropione [mart.]
p-hydroxypropiophenone [jan]
CCG-214030
SCHEMBL440470
tox21_110822_1
4-hydroxy propiophenone
4'-hydroxy-propiophenone
W-104544
p.o.p.
4-hydroxypropiophenon
possipion
4-propanoylphenol
HY-B1353
CS-7973
OPERA_ID_1001
AB00384258_14
mfcd00002361
sr-01000002967
SR-01000002967-2
4`-hydroxypropiophenone
p-hydroxypropiophenon
SY003666
4 inverted exclamation mark -hydroxypropiophenone
chlorhexidinedigluconate
AS-12055
BCP26379
Q19598411
BRD-K07441213-001-14-8
EN300-21481
4?-hydroxypropiophenone
AC7855
Z104499156

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Occurs in Manufacturing (1 Product(s))

Product Categories

Product CategoryProducts
Beauty & Personal Care1

Products

ProductBrandCategoryCompounds Matched from IngredientsDate Retrieved
Eczema Honey Multi Peptide Eye Cream -- 0.5 ozEczema HoneyBeauty & Personal Carecitric acid, chlorhexidine digluconate, benzoic acid, escin, cetyl alcohol, cetyl palmitate, chrysin, citric acid, tocopherol, hydroxyapatite, ethylhexylglycerin, tocopherol, glyceryl stearates, glycerin, n-hydroxysuccinimide, oat, phenoxyethanol, sodium citrate2024-11-29 10:47:42

Drug Classes (1)

ClassDescription
acetophenonesA class or aromatic ketone consisting of acetophenone, PhC(=O)CH3, and its substituted derivatives.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (21)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency0.00320.003245.467312,589.2998AID2517
AR proteinHomo sapiens (human)Potency31.67040.000221.22318,912.5098AID1259243; AID1259247
thioredoxin glutathione reductaseSchistosoma mansoniPotency89.12510.100022.9075100.0000AID485364
estrogen receptor 2 (ER beta)Homo sapiens (human)Potency13.33320.000657.913322,387.1992AID1259377
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency26.77970.001022.650876.6163AID1224838; AID1224893
nonstructural protein 1Influenza A virus (A/WSN/1933(H1N1))Potency0.31620.28189.721235.4813AID2326
estrogen nuclear receptor alphaHomo sapiens (human)Potency0.67400.000229.305416,493.5996AID743075
GVesicular stomatitis virusPotency4.89750.01238.964839.8107AID1645842
IDH1Homo sapiens (human)Potency5.80480.005210.865235.4813AID686970
chromobox protein homolog 1Homo sapiens (human)Potency89.12510.006026.168889.1251AID540317
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency26.60110.000627.21521,122.0200AID743202; AID743219
gemininHomo sapiens (human)Potency0.00460.004611.374133.4983AID624296
peripheral myelin protein 22Rattus norvegicus (Norway rat)Potency0.11420.005612.367736.1254AID624032
Rap guanine nucleotide exchange factor 3Homo sapiens (human)Potency125.89206.309660.2008112.2020AID720707
Interferon betaHomo sapiens (human)Potency4.89750.00339.158239.8107AID1645842
HLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)Potency4.89750.01238.964839.8107AID1645842
Inositol hexakisphosphate kinase 1Homo sapiens (human)Potency4.89750.01238.964839.8107AID1645842
cytochrome P450 2C9, partialHomo sapiens (human)Potency4.89750.01238.964839.8107AID1645842
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Testosterone 17-beta-dehydrogenase 3Homo sapiens (human)IC50 (µMol)150.56000.00261.76469.3000AID270049
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (96)

Processvia Protein(s)Taxonomy
angiogenesisRap guanine nucleotide exchange factor 3Homo sapiens (human)
adaptive immune responseRap guanine nucleotide exchange factor 3Homo sapiens (human)
signal transductionRap guanine nucleotide exchange factor 3Homo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayRap guanine nucleotide exchange factor 3Homo sapiens (human)
associative learningRap guanine nucleotide exchange factor 3Homo sapiens (human)
Rap protein signal transductionRap guanine nucleotide exchange factor 3Homo sapiens (human)
regulation of actin cytoskeleton organizationRap guanine nucleotide exchange factor 3Homo sapiens (human)
negative regulation of syncytium formation by plasma membrane fusionRap guanine nucleotide exchange factor 3Homo sapiens (human)
intracellular signal transductionRap guanine nucleotide exchange factor 3Homo sapiens (human)
positive regulation of GTPase activityRap guanine nucleotide exchange factor 3Homo sapiens (human)
regulation of angiogenesisRap guanine nucleotide exchange factor 3Homo sapiens (human)
positive regulation of angiogenesisRap guanine nucleotide exchange factor 3Homo sapiens (human)
positive regulation of protein export from nucleusRap guanine nucleotide exchange factor 3Homo sapiens (human)
positive regulation of stress fiber assemblyRap guanine nucleotide exchange factor 3Homo sapiens (human)
regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionRap guanine nucleotide exchange factor 3Homo sapiens (human)
positive regulation of syncytium formation by plasma membrane fusionRap guanine nucleotide exchange factor 3Homo sapiens (human)
establishment of endothelial barrierRap guanine nucleotide exchange factor 3Homo sapiens (human)
cellular response to cAMPRap guanine nucleotide exchange factor 3Homo sapiens (human)
Ras protein signal transductionRap guanine nucleotide exchange factor 3Homo sapiens (human)
regulation of insulin secretionRap guanine nucleotide exchange factor 3Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
positive regulation of T cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
adaptive immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independentHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of T cell anergyHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
defense responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
detection of bacteriumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-12 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-6 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protection from natural killer cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
innate immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of dendritic cell differentiationHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class IbHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
androgen biosynthetic processTestosterone 17-beta-dehydrogenase 3Homo sapiens (human)
male genitalia developmentTestosterone 17-beta-dehydrogenase 3Homo sapiens (human)
testosterone biosynthetic processTestosterone 17-beta-dehydrogenase 3Homo sapiens (human)
steroid biosynthetic processTestosterone 17-beta-dehydrogenase 3Homo sapiens (human)
succinate metabolic processSuccinate-semialdehyde dehydrogenase, mitochondrialHomo sapiens (human)
glutamate metabolic processSuccinate-semialdehyde dehydrogenase, mitochondrialHomo sapiens (human)
central nervous system developmentSuccinate-semialdehyde dehydrogenase, mitochondrialHomo sapiens (human)
gamma-aminobutyric acid catabolic processSuccinate-semialdehyde dehydrogenase, mitochondrialHomo sapiens (human)
post-embryonic developmentSuccinate-semialdehyde dehydrogenase, mitochondrialHomo sapiens (human)
synaptic transmission, GABAergicSuccinate-semialdehyde dehydrogenase, mitochondrialHomo sapiens (human)
response to hypoxia4-aminobutyrate aminotransferase, mitochondrialHomo sapiens (human)
copulation4-aminobutyrate aminotransferase, mitochondrialHomo sapiens (human)
locomotory behavior4-aminobutyrate aminotransferase, mitochondrialHomo sapiens (human)
response to xenobiotic stimulus4-aminobutyrate aminotransferase, mitochondrialHomo sapiens (human)
gamma-aminobutyric acid metabolic process4-aminobutyrate aminotransferase, mitochondrialHomo sapiens (human)
gamma-aminobutyric acid biosynthetic process4-aminobutyrate aminotransferase, mitochondrialHomo sapiens (human)
response to iron ion4-aminobutyrate aminotransferase, mitochondrialHomo sapiens (human)
negative regulation of gamma-aminobutyric acid secretion4-aminobutyrate aminotransferase, mitochondrialHomo sapiens (human)
cerebellum development4-aminobutyrate aminotransferase, mitochondrialHomo sapiens (human)
positive regulation of heat generation4-aminobutyrate aminotransferase, mitochondrialHomo sapiens (human)
positive regulation of insulin secretion4-aminobutyrate aminotransferase, mitochondrialHomo sapiens (human)
negative regulation of dopamine secretion4-aminobutyrate aminotransferase, mitochondrialHomo sapiens (human)
response to nicotine4-aminobutyrate aminotransferase, mitochondrialHomo sapiens (human)
exploration behavior4-aminobutyrate aminotransferase, mitochondrialHomo sapiens (human)
response to ethanol4-aminobutyrate aminotransferase, mitochondrialHomo sapiens (human)
negative regulation of blood pressure4-aminobutyrate aminotransferase, mitochondrialHomo sapiens (human)
positive regulation of dopamine metabolic process4-aminobutyrate aminotransferase, mitochondrialHomo sapiens (human)
behavioral response to cocaine4-aminobutyrate aminotransferase, mitochondrialHomo sapiens (human)
positive regulation of uterine smooth muscle contraction4-aminobutyrate aminotransferase, mitochondrialHomo sapiens (human)
positive regulation of inhibitory postsynaptic potential4-aminobutyrate aminotransferase, mitochondrialHomo sapiens (human)
positive regulation of prolactin secretion4-aminobutyrate aminotransferase, mitochondrialHomo sapiens (human)
positive regulation of aspartate secretion4-aminobutyrate aminotransferase, mitochondrialHomo sapiens (human)
gamma-aminobutyric acid catabolic process4-aminobutyrate aminotransferase, mitochondrialHomo sapiens (human)
inositol phosphate metabolic processInositol hexakisphosphate kinase 1Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
negative regulation of cold-induced thermogenesisInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (34)

Processvia Protein(s)Taxonomy
guanyl-nucleotide exchange factor activityRap guanine nucleotide exchange factor 3Homo sapiens (human)
protein bindingRap guanine nucleotide exchange factor 3Homo sapiens (human)
protein domain specific bindingRap guanine nucleotide exchange factor 3Homo sapiens (human)
cAMP bindingRap guanine nucleotide exchange factor 3Homo sapiens (human)
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
signaling receptor bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
peptide antigen bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein-folding chaperone bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
estradiol 17-beta-dehydrogenase [NAD(P)] activityTestosterone 17-beta-dehydrogenase 3Homo sapiens (human)
testosterone dehydrogenase [NAD(P)] activityTestosterone 17-beta-dehydrogenase 3Homo sapiens (human)
testosterone 17-beta-dehydrogenase (NADP+) activityTestosterone 17-beta-dehydrogenase 3Homo sapiens (human)
17-beta-hydroxysteroid dehydrogenase (NADP+) activityTestosterone 17-beta-dehydrogenase 3Homo sapiens (human)
succinate-semialdehyde dehydrogenase (NAD+) activitySuccinate-semialdehyde dehydrogenase, mitochondrialHomo sapiens (human)
identical protein bindingSuccinate-semialdehyde dehydrogenase, mitochondrialHomo sapiens (human)
4-aminobutyrate transaminase activity4-aminobutyrate aminotransferase, mitochondrialHomo sapiens (human)
pyridoxal phosphate binding4-aminobutyrate aminotransferase, mitochondrialHomo sapiens (human)
succinate-semialdehyde dehydrogenase binding4-aminobutyrate aminotransferase, mitochondrialHomo sapiens (human)
4-aminobutyrate:2-oxoglutarate transaminase activity4-aminobutyrate aminotransferase, mitochondrialHomo sapiens (human)
identical protein binding4-aminobutyrate aminotransferase, mitochondrialHomo sapiens (human)
metal ion binding4-aminobutyrate aminotransferase, mitochondrialHomo sapiens (human)
(S)-3-amino-2-methylpropionate transaminase activity4-aminobutyrate aminotransferase, mitochondrialHomo sapiens (human)
iron-sulfur cluster binding4-aminobutyrate aminotransferase, mitochondrialHomo sapiens (human)
inositol-1,3,4,5,6-pentakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol heptakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
protein bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
ATP bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 1-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 3-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol 5-diphosphate pentakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol diphosphate tetrakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (33)

Processvia Protein(s)Taxonomy
plasma membraneRap guanine nucleotide exchange factor 3Homo sapiens (human)
cortical actin cytoskeletonRap guanine nucleotide exchange factor 3Homo sapiens (human)
plasma membraneRap guanine nucleotide exchange factor 3Homo sapiens (human)
microvillusRap guanine nucleotide exchange factor 3Homo sapiens (human)
endomembrane systemRap guanine nucleotide exchange factor 3Homo sapiens (human)
membraneRap guanine nucleotide exchange factor 3Homo sapiens (human)
lamellipodiumRap guanine nucleotide exchange factor 3Homo sapiens (human)
filopodiumRap guanine nucleotide exchange factor 3Homo sapiens (human)
extracellular exosomeRap guanine nucleotide exchange factor 3Homo sapiens (human)
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
Golgi membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
endoplasmic reticulumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
Golgi apparatusHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
cell surfaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
ER to Golgi transport vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
secretory granule membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
phagocytic vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
early endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
recycling endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular exosomeHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
lumenal side of endoplasmic reticulum membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
MHC class I protein complexHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular spaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
external side of plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
endoplasmic reticulumTestosterone 17-beta-dehydrogenase 3Homo sapiens (human)
endoplasmic reticulum membraneTestosterone 17-beta-dehydrogenase 3Homo sapiens (human)
intracellular membrane-bounded organelleTestosterone 17-beta-dehydrogenase 3Homo sapiens (human)
endoplasmic reticulumTestosterone 17-beta-dehydrogenase 3Homo sapiens (human)
mitochondrionSuccinate-semialdehyde dehydrogenase, mitochondrialHomo sapiens (human)
mitochondrial matrixSuccinate-semialdehyde dehydrogenase, mitochondrialHomo sapiens (human)
synapseSuccinate-semialdehyde dehydrogenase, mitochondrialHomo sapiens (human)
mitochondrionSuccinate-semialdehyde dehydrogenase, mitochondrialHomo sapiens (human)
mitochondrion4-aminobutyrate aminotransferase, mitochondrialHomo sapiens (human)
mitochondrial matrix4-aminobutyrate aminotransferase, mitochondrialHomo sapiens (human)
4-aminobutyrate transaminase complex4-aminobutyrate aminotransferase, mitochondrialHomo sapiens (human)
mitochondrion4-aminobutyrate aminotransferase, mitochondrialHomo sapiens (human)
fibrillar centerInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
cytosolInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleusInositol hexakisphosphate kinase 1Homo sapiens (human)
cytoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (82)

Assay IDTitleYearJournalArticle
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID270050Inhibition of 17beta-HSD3 at 100 uM2006Bioorganic & medicinal chemistry letters, Sep-01, Volume: 16, Issue:17
Synthesis, biochemical evaluation and rationalisation of the inhibitory activity of a series of 4-hydroxyphenyl ketones as potential inhibitors of 17beta-hydroxysteroid dehydrogenase type 3 (17beta-HSD3).
AID1325080Antimelanogenic activity in theophylline-stimulated mouse B16-4A5 cells assessed as inhibition of melanogenesis at 30 uM after 72 hrs relative to control2016Bioorganic & medicinal chemistry, 12-01, Volume: 24, Issue:23
Melanogenesis inhibitory activity of a 7-O-9'-linked neolignan from Alpinia galanga fruit.
AID1325089Cytotoxicity against theophylline-stimulated mouse B16-4A5 cells assessed as cell viability at 100 uM after 72 hrs by MTT assay relative to control2016Bioorganic & medicinal chemistry, 12-01, Volume: 24, Issue:23
Melanogenesis inhibitory activity of a 7-O-9'-linked neolignan from Alpinia galanga fruit.
AID1325087Cytotoxicity against theophylline-stimulated mouse B16-4A5 cells assessed as cell viability at 10 uM after 72 hrs by MTT assay relative to control2016Bioorganic & medicinal chemistry, 12-01, Volume: 24, Issue:23
Melanogenesis inhibitory activity of a 7-O-9'-linked neolignan from Alpinia galanga fruit.
AID1145610Dissociation constant, pKa of the compound at pH 6.81977Journal of medicinal chemistry, Jan, Volume: 20, Issue:1
Use of distribution coefficients in quantitative structure-activity relationships.
AID1325081Antimelanogenic activity in theophylline-stimulated mouse B16-4A5 cells assessed as inhibition of melanogenesis at 100 uM after 72 hrs relative to control2016Bioorganic & medicinal chemistry, 12-01, Volume: 24, Issue:23
Melanogenesis inhibitory activity of a 7-O-9'-linked neolignan from Alpinia galanga fruit.
AID569157Inhibition of migration of human Hs578Ts(i)8 cells at 100 uM after 24 hrs2011Bioorganic & medicinal chemistry letters, Feb-01, Volume: 21, Issue:3
Inhibitory effects of ethacrynic acid analogues lacking the α,β-unsaturated carbonyl unit and para-acylated phenols on human cancer cells.
AID1325094Inhibition of mushroom tyrosinase activity using L-tyrosine as substrate at 100 uM after 30 mins2016Bioorganic & medicinal chemistry, 12-01, Volume: 24, Issue:23
Melanogenesis inhibitory activity of a 7-O-9'-linked neolignan from Alpinia galanga fruit.
AID270049Inhibition of 17beta-HSD32006Bioorganic & medicinal chemistry letters, Sep-01, Volume: 16, Issue:17
Synthesis, biochemical evaluation and rationalisation of the inhibitory activity of a series of 4-hydroxyphenyl ketones as potential inhibitors of 17beta-hydroxysteroid dehydrogenase type 3 (17beta-HSD3).
AID346025Binding affinity to beta cyclodextrin2009Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2
Convenient QSAR model for predicting the complexation of structurally diverse compounds with beta-cyclodextrins.
AID1325095Inhibition of mushroom tyrosinase activity using L-DOPA as substrate at 10 uM after 30 mins2016Bioorganic & medicinal chemistry, 12-01, Volume: 24, Issue:23
Melanogenesis inhibitory activity of a 7-O-9'-linked neolignan from Alpinia galanga fruit.
AID1325093Inhibition of mushroom tyrosinase activity using L-tyrosine as substrate at 10 uM after 30 mins2016Bioorganic & medicinal chemistry, 12-01, Volume: 24, Issue:23
Melanogenesis inhibitory activity of a 7-O-9'-linked neolignan from Alpinia galanga fruit.
AID1325088Cytotoxicity against theophylline-stimulated mouse B16-4A5 cells assessed as cell viability at 30 uM after 72 hrs by MTT assay relative to control2016Bioorganic & medicinal chemistry, 12-01, Volume: 24, Issue:23
Melanogenesis inhibitory activity of a 7-O-9'-linked neolignan from Alpinia galanga fruit.
AID1145608Drug absorption in anesthetized rat colon at pH 6.81977Journal of medicinal chemistry, Jan, Volume: 20, Issue:1
Use of distribution coefficients in quantitative structure-activity relationships.
AID588220Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset2008Toxicology mechanisms and methods, , Volume: 18, Issue:2-3
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
AID569159Inhibition of migration of human Hs578Ts(i)8 cells assessed as reduction in cell viability after 24 hrs2011Bioorganic & medicinal chemistry letters, Feb-01, Volume: 21, Issue:3
Inhibitory effects of ethacrynic acid analogues lacking the α,β-unsaturated carbonyl unit and para-acylated phenols on human cancer cells.
AID260086Inhibitory activity against GABAT2006Bioorganic & medicinal chemistry letters, Feb, Volume: 16, Issue:3
Inhibition of GABA shunt enzymes' activity by 4-hydroxybenzaldehyde derivatives.
AID569158Inhibition of migration of human C4-2B cells assessed as reduction in cell viability after 24 hrs2011Bioorganic & medicinal chemistry letters, Feb-01, Volume: 21, Issue:3
Inhibitory effects of ethacrynic acid analogues lacking the α,β-unsaturated carbonyl unit and para-acylated phenols on human cancer cells.
AID1325077Antimelanogenic activity in theophylline-stimulated mouse B16-4A5 cells assessed as inhibition of melanogenesis at 3 uM after 72 hrs relative to control2016Bioorganic & medicinal chemistry, 12-01, Volume: 24, Issue:23
Melanogenesis inhibitory activity of a 7-O-9'-linked neolignan from Alpinia galanga fruit.
AID1325096Inhibition of mushroom tyrosinase activity using L-DOPA as substrate at 100 uM after 30 mins2016Bioorganic & medicinal chemistry, 12-01, Volume: 24, Issue:23
Melanogenesis inhibitory activity of a 7-O-9'-linked neolignan from Alpinia galanga fruit.
AID1145606Octanol-aqueous phase partition coefficient, log P of the compound1977Journal of medicinal chemistry, Jan, Volume: 20, Issue:1
Use of distribution coefficients in quantitative structure-activity relationships.
AID569156Inhibition of migration of human C4-2B cells at 100 uM after 24 hrs2011Bioorganic & medicinal chemistry letters, Feb-01, Volume: 21, Issue:3
Inhibitory effects of ethacrynic acid analogues lacking the α,β-unsaturated carbonyl unit and para-acylated phenols on human cancer cells.
AID1145607Octanol-aqueous phase distribution coefficient, log D of the compound1977Journal of medicinal chemistry, Jan, Volume: 20, Issue:1
Use of distribution coefficients in quantitative structure-activity relationships.
AID69224Relative binding affinity ( relative to estradiol) to mouse estrogen receptor.1998Journal of medicinal chemistry, Jun-18, Volume: 41, Issue:13
Three-dimensional quantitative structure-activity relationship study of nonsteroidal estrogen receptor ligands using the comparative molecular field analysis/cross-validated r2-guided region selection approach.
AID1325078Antimelanogenic activity in theophylline-stimulated mouse B16-4A5 cells assessed as inhibition of melanogenesis at 10 uM after 72 hrs relative to control2016Bioorganic & medicinal chemistry, 12-01, Volume: 24, Issue:23
Melanogenesis inhibitory activity of a 7-O-9'-linked neolignan from Alpinia galanga fruit.
AID1325086Cytotoxicity against theophylline-stimulated mouse B16-4A5 cells assessed as cell viability at 3 uM after 72 hrs by MTT assay relative to control2016Bioorganic & medicinal chemistry, 12-01, Volume: 24, Issue:23
Melanogenesis inhibitory activity of a 7-O-9'-linked neolignan from Alpinia galanga fruit.
AID260087Inhibitory activity against SSADH2006Bioorganic & medicinal chemistry letters, Feb, Volume: 16, Issue:3
Inhibition of GABA shunt enzymes' activity by 4-hydroxybenzaldehyde derivatives.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1224864HCS microscopy assay (F508del-CFTR)2016PloS one, , Volume: 11, Issue:10
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (103)

TimeframeStudies, This Drug (%)All Drugs %
pre-199075 (72.82)18.7374
1990's5 (4.85)18.2507
2000's6 (5.83)29.6817
2010's11 (10.68)24.3611
2020's6 (5.83)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 29.63

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index29.63 (24.57)
Research Supply Index4.78 (2.92)
Research Growth Index4.56 (4.65)
Search Engine Demand Index35.84 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (29.63)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies1 (0.85%)4.05%
Observational0 (0.00%)0.25%
Other117 (99.15%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]